Keyphrases
Sodium-glucose Cotransporter 2 Inhibitors (SGLT2i)
97%
Type 2 Diabetic Patients
83%
National Cohort Study
51%
Dipeptidyl peptidase-4 (DPP-4)
41%
South Korea
37%
Type 2 Diabetes Mellitus (T2DM)
32%
Safety Outcomes
24%
Seizure
24%
Acute Heart Failure
24%
Meta-analysis
24%
Cardiovascular Safety
24%
Autism Spectrum Disorder
24%
Case-case
24%
Amputation
24%
Discharge Outcomes
24%
Diuretic Use
24%
Adverse Respiratory Events
24%
Attention Deficit Hyperactivity Disorder
24%
Metformin
24%
Evogliptin
24%
Cardiovascular Disease
24%
Tramadol Use
24%
Oral Corticosteroids
24%
Tramadol
24%
Case-time-control
24%
Atopic Dermatitis
24%
Systematic Meta-analysis
24%
Dual Therapy
24%
Triple Therapy
24%
Antipsychotics
24%
Angiotensin Receptor-neprilysin Inhibitor
24%
Heart Failure Admission
24%
Target Trial Emulation
24%
Adjusted Odds Ratio
23%
Adverse Events
19%
Confidence Interval
18%
Hazard Ratio
17%
Propensity Score Matching
14%
Heart Failure
13%
Sulfonylurea
12%
Myocardial Infarction
11%
Heart Failure Readmission
10%
Cardiovascular Mortality
10%
Individual Outcomes
10%
Response Time Analysis
9%
Case-crossover
9%
Adjusted Dose
9%
Cerebrovascular Accident
9%
Cardiovascular Risk
9%
Routine Clinical Practice
8%
Medicine and Dentistry
Sodium Glucose Cotransporter 2 Inhibitor
97%
Patient with Type 2 Diabetes
83%
Cohort Analysis
76%
Congestive Heart Failure
55%
Dipeptidyl Peptidase-4 Inhibitor
41%
Maturity Onset Diabetes of the Young
33%
Cardiovascular System
29%
Acute Decompensated Heart Failure
24%
Cardiovascular Disease
24%
Attention Deficit Disorder
24%
Adverse Event
24%
Amputation
24%
Evogliptin
24%
Atopic Dermatitis
24%
Tramadol
24%
Glycon
24%
Pervasive Developmental Disorder
24%
Meta-Analysis
24%
Systematic Review
24%
Epileptic Seizure
24%
Enkephalinase Inhibitor
24%
Angiotensin Receptor
24%
Diuretics
24%
Antipsychotic
24%
Hazard Ratio
23%
Odds Ratio
19%
Respiratory Physiology
14%
Proportional Hazards Model
12%
Sulfonylurea
12%
Myocardial Infarction
11%
Acute Respiratory Distress Syndrome
9%
Respiratory Failure
9%
Pulmonary Edema
9%
Dose Response
6%
Clinician
6%
Propensity Score Matching
6%
Early Intervention
6%
Nerve Cell Differentiation
6%
Mental Health
6%
Diseases
6%
Retrospective Cohort Study
5%
Cardiovascular Mortality
5%
Case-Control Study
5%
Pharmacology, Toxicology and Pharmaceutical Science
Non Insulin Dependent Diabetes Mellitus
100%
Sodium Glucose Cotransporter 2 Inhibitor
97%
Cohort Study
76%
Congestive Heart Failure
55%
Dipeptidyl Peptidase IV Inhibitor
41%
Antipsychotic
24%
Tramadol
24%
Evogliptin
24%
Adverse Event
24%
Acute Heart Failure
24%
Atopic Dermatitis
24%
Metformin
24%
Attention Deficit Disorder
24%
Enkephalinase Inhibitor
24%
Diuretics
24%
Angiotensin Receptor
24%
Cardiovascular Disease
24%
Sulfonylurea
12%
Heart Infarction
11%
Lung Edema
9%
Adult Respiratory Distress Syndrome
9%
Respiratory Failure
9%
Diseases
6%
Cardiovascular Mortality
5%
Case-Control Study
5%